Aditya Bardia

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells

  Proceedings of the National Academy of Sciences · 2026-06-17

• Activating a B cell immune response regresses immunologically cold tumours

  Nature Nanotechnology · 2026-06-01 · 1 citations

• Treatment response and clinical outcomes of patients with triple negative invasive apocrine breast carcinoma.

  Journal of Clinical Oncology · 2026-05-28

• Prognostic impact of <i>PIK3CA</i> amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC).

  Journal of Clinical Oncology · 2026-05-27

• KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy

  Clinical Cancer Research · 2025-12-17

• Supplementary Fig. 2 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

  2025-11-25

• Supplementary Fig. 6 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplementary Data 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplementary Fig. 3 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

  2025-11-25

• Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

  2025-11-25

• Supplementary Fig. 4 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

  2025-11-25

• Supplementary Fig. 5 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplementary Fig. 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

  2025-11-25

• Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

  2025-11-25

• Clinical and Genomic Factors Associated with Elacestrant Outcomes in <i>ESR1-</i> Mutant Metastatic Breast Cancer

  Clinical Cancer Research · 2025-11-07 · 2 citations

• Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis

  Targeted Oncology · 2025-11-01 · 2 citations

• Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ <i>ERBB2</i> -Negative Early Breast Cancer

  JAMA Oncology · 2025-09-25 · 18 citations